Bone marrow-derived liver-committed stem cell mobilization by G-CSF to enhance liver regeneration after hepatectomy
| ISRCTN | ISRCTN16342840 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN16342840 |
| Protocol serial number | N/A |
| Sponsor | State University of Campinas (Brazil) |
| Funder | Brazilian National Counsel of Technological and Scientific Development |
- Submission date
- 22/12/2015
- Registration date
- 08/01/2016
- Last edited
- 07/01/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Liver tumors usually require surgical treatment. Surgery to remove part of the liver (partial hepatectomy) is commonly performed. After hepatectomy regeneration of the liver is very important to maintain liver function. Stem cells from the bone marrow could migrate from the bloodstream to the liver and contribute to liver regeneration. Granulocyte-colony stimulating factor (G-CSF) can be given to patients to stimulate the bone marrow to produce and release the stem cells. The aim of this study is to find out whether infusing G-CSF before partial hepatectomy mobilizes patients’ stem cells and improves liver recovery.
Who can participate?
Patients aged 18 to 75 with benign or malignant liver tumors and undergoing partial hepatectomy.
What does the study involve?
Participants are randomly allocated to one of two groups. In one group participants are treated with G-CSF every day in the morning for five consecutive days before undergoing partial hepatectomy. In the other group participants are treated with saline (salt solution) in the same manner before undergoing partial hepatectomy. Blood samples are collected from the two groups to investigate the presence of stem cells in the blood. The results are compared with the results obtained from healthy volunteers. All patients are monitored daily by physical examination and laboratory tests. CT scans are performed to evaluate liver volume, tumor mass and liver recovery.
What are the possible benefits and risks of participating?
The benefit would be enhanced remnant liver recovery after hepatectomy. G-CSF has been used with no harm for more than 30 years.
Where is the study run from?
1. Clinic Hospital, Barão Geraldo (Brazil)
2. Haematology Hemotherapy Centre, Barão Geraldo (Brazil)
When is the study starting and how long is it expected to run for?
August 2008 to July 2015
Who is funding the study?
1. Norrbacka-Eugenia Foundation (Sweden)
2. Foundation Sunnerdahls Disability Fund (Sweden)
3. Promobilia Foundation (Sweden)
Who is the main contact?
1. Dr Ângela Luzo (scientific)
2. Dr Ilka Boin (scientific)
Contact information
Scientific
Como chegar ao Hemocentro
Rua Carlos Chagas, 480
Campinas
13083-970
Brazil
 ORCID ID |
0000-0002-1422-9119 |
|---|
Scientific
Cidade Universitária
Rua Carlos Chagas 420
Campinas
13083-878
Brazil
| ORCID ID |
0000-0002-1165-2149 |
|---|
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective double-blind randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | G-CSF mobilization in the pre-operatory period to enhance remnant liver recovery after hepatectomy: a randomised controlled trial |
| Study objectives | Pre operative G-CSF mobilization might recruit bone marrow–derived liver committed stem cells (BMDLCSC), immunophenotyped as CD34+/Lin-/CXCR4+/SDF1+ stem cells, improving remnant liver recovery in patients undergoing extensive PH. |
| Ethics approval(s) | 1. Ethics Committee of the Faculty of Medical Sciences (State University of Campinas), 15/12/2009, ref: 996/2008 2. Brasilian National Ethics Committee (CONEP), 29/01/2010, ref: 061/2010 |
| Health condition(s) or problem(s) studied | Controlled primary neoplasia disease |
| Intervention | The presence of bone marrow-derived liver committed stem cells, immunophenotyping as D34+/Lin-/CXCR4+/SDF1+ stem cells, were previously investigated by flow cytometry in the peripheral blood of 9 adult healthy volunteers, with the same median age of the eligible patients, in order to be used as healthy normal controls of these cells. All patients were hospitalized in the Liver Unit one day prior to mobilization or infusion of NaCl 0.9%. In the intervention group bone marrow stem cells mobilization was induced by G-CSF (Granulokyn, Roche), administered via subcutaneous 10 µg/kg every day, in the morning during five consecutive days. The control group received subcutaneous NaCl 0.9% in the same volume as G-CSF in the same manner (every day, in the morning during five consecutive days). Before the beginning of the mobilization protocol, blood samples were collected from the two groups to perform flow cytometry analyses to investigate the previous presence of BMDLCSC (CD34+ /Lin-/CXCR4+/SDF1 + stem cells) in the peripheral blood. The results were compared with the ones obtained from healthy donor controls. All patients were submitted to PH on the 5th day of G-CSF/NaCL 0.9% mobilization, and monitored daily by physical examination and laboratory tests. Abdominal CT was performed to evaluate hepatic volume, the amount of tumor mass pre partial liver resection and in the post surgery period, and on day 10, 30 and 60 to evaluate the remnant liver growth. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure(s) |
The effectiveness of recruitment and release of bone marrow-derived liver-committed stem cells to the peripheral blood by granulocyte colony stimulating factor (GCSF) bone marrow mobilization at improving remnant liver recovery in patients undergoing extensive liver resections. |
| Key secondary outcome measure(s) |
Patient clinical and laboratory exams were performed during the recruitment phase and on day 0 before GCSF/NaCl 0.9% administration, and days 5, 10 and 60. |
| Completion date | 01/07/2015 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 79 |
| Key inclusion criteria | 1. Aged between 18 and 75 years 2. Controlled primary neoplasia disease 3. Absence of clinical, laboratorial and radiological evidence of tumor metastasis |
| Key exclusion criteria | 1. Chronic hepatic insufficiency 2. Hepatic encephalopathy 3. Coagulopathy 4. Presence of hepatoblastoma 5. Disseminated intravascular coagulation 5. Renal or cardiac insufficiency 5. Acute infection 6. Sepsis (defined by the criteria of the Society of Critical Care Medicine and American College of Chest Physicians, 1992) 7. Those enlisted for liver transplantation. |
| Date of first enrolment | 01/02/2010 |
| Date of final enrolment | 01/03/2011 |
Locations
Countries of recruitment
- Brazil
Study participating centres
Barão Geraldo
Campinas
13083-888
Brazil
Barão Geraldo
Campinas
13083-970
Brazil
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
